RAD Stock Overview
Engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Radiopharm Theranostics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.035 |
| 52 Week High | AU$0.15 |
| 52 Week Low | AU$0.027 |
| Beta | 0.83 |
| 11 Month Change | -5.41% |
| 3 Month Change | 2.94% |
| 1 Year Change | -68.18% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -91.25% |
Recent News & Updates
Shareholder Returns
| RAD | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | 16.7% | -1.6% | 1.7% |
| 1Y | -68.2% | 14.0% | 12.4% |
Return vs Industry: RAD underperformed the Australian Biotechs industry which returned 14% over the past year.
Return vs Market: RAD underperformed the Australian Market which returned 12.4% over the past year.
Price Volatility
| RAD volatility | |
|---|---|
| RAD Average Weekly Movement | 11.7% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 8.5% |
| 10% most volatile stocks in AU Market | 16.8% |
| 10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: RAD's share price has been volatile over the past 3 months.
Volatility Over Time: RAD's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2021 | n/a | Riccardo Canevari | www.radiopharmtheranostics.com |
Radiopharm Theranostics Limited engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs. It is developing its lead products comprising Nano-mAbs and AVB6 Integrin. The company was incorporated in 2021 and is based in Carlton, Australia.
Radiopharm Theranostics Limited Fundamentals Summary
| RAD fundamental statistics | |
|---|---|
| Market cap | AU$62.38m |
| Earnings (TTM) | -AU$47.95m |
| Revenue (TTM) | AU$1.64m |
44.3x
P/S Ratio-1.5x
P/E RatioIs RAD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RAD income statement (TTM) | |
|---|---|
| Revenue | AU$1.64m |
| Cost of Revenue | AU$21.61m |
| Gross Profit | -AU$19.97m |
| Other Expenses | AU$27.98m |
| Earnings | -AU$47.95m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.023 |
| Gross Margin | -1,215.69% |
| Net Profit Margin | -2,919.65% |
| Debt/Equity Ratio | 0% |
How did RAD perform over the long term?
See historical performance and comparison